Interstitial Lung Disease: Why morphology isn't the full picture

Written by The Life Science Feed Editorial Team · Published 28 September 2026 · Edited by William Lopes

Interstitial lung diseases (ILDs) represent a heterogeneous group of disorders, often challenging to diagnose and manage due to their varied presentations and progressive nature. For too long, clinicians have relied on broad categorisations, but a deeper understanding of the genetic underpinnings is now refining this approach. This evolving knowledge promises more precise diagnostic pathways and targeted therapeutic strategies.

KEY TAKEAWAYS

- The Pivot: Genetic research is increasingly defining ILD subtypes, moving beyond purely morphological classifications.
- The Data: While no specific numeric data from trials is available here, the consistent identification of genetic variants points to a molecular basis for disease progression.
- The Action: Clinicians should consider genetic factors in complex ILD cases, especially when family history or atypical presentations are present, to guide diagnosis and potentially future treatment.

Interstitial lung diseases encompass over 200 distinct conditions, all characterised by progressive scarring of the lung tissue. This fibrosis leads to impaired gas exchange, ultimately causing respiratory failure. The clinical course, however, varies widely, from rapidly progressive forms like idiopathic pulmonary fibrosis (IPF) to more indolent conditions associated with connective tissue diseases. The challenge for clinicians has always been to differentiate these conditions accurately and predict their trajectory, a task made difficult by overlapping symptoms and radiological features. The early diagnosis of pulmonary fibrosis remains a significant hurdle.

Standard diagnostic approaches typically involve high-resolution computed tomography (HRCT) and, in some cases, surgical lung biopsy. These methods provide vital morphological information, but they often fall short in explaining the underlying biological drivers of the disease. This is particularly true for conditions that do not fit neatly into established categories, leading to diagnoses of unclassifiable ILD. Such cases highlight the unmet need for more precise diagnostic tools that can identify specific pathogenic pathways.

The Genetic Architecture of ILD

The recognition that genetics play a substantial role in the predisposition and progression of ILDs has been a significant development. While many ILDs are considered sporadic, a growing number of familial cases and genetic associations have been identified. These discoveries are beginning to unravel the complex relationship between genetic susceptibility and environmental triggers, offering a more complete picture of disease pathogenesis. Understanding these genetic factors is becoming as important as the clinical presentation itself, guiding both diagnosis and prognosis.

One of the most well-studied genetic associations in ILD is with mutations in genes encoding telomerase components, such as TERT and TERC. These mutations are linked to familial pulmonary fibrosis and a subset of sporadic IPF cases. Telomeres are protective caps at the ends of chromosomes, and their shortening can lead to cellular senescence and impaired tissue repair, particularly in rapidly dividing cells like those in the lung epithelium. Patients with these mutations often present with shorter telomeres, even in the absence of overt lung disease, suggesting a systemic predisposition.
Beyond telomerase, other genetic variants have been implicated. For example, mutations in surfactant protein genes (SFTPC, SFTPA2, ABCA3) are associated with various forms of ILD, particularly in paediatric populations and some adult cases. These proteins are critical for maintaining alveolar stability and function. Defects in their production or processing can lead to surfactant dysfunction, inflammation, and subsequent fibrosis. The clinical presentations linked to these mutations can range from acute respiratory distress syndrome in neonates to chronic progressive fibrosis in adults, underscoring the broad phenotypic spectrum of genetically driven ILDs.
Another area of intense research involves genes related to mucin production and clearance, such as MUC5B. A common variant in the MUC5B promoter region is a strong risk factor for IPF and other fibrotic lung diseases. This variant leads to overexpression of MUC5B, a secreted mucin, which is thought to contribute to the formation of abnormal mucus plugs and impaired mucociliary clearance in the small airways. This creates a microenvironment conducive to inflammation and fibrosis, highlighting a potential therapeutic target for specific patient subsets. The mechanisms of surfactant overproduction are distinct but also illustrate the complexity of lung protein dysregulation.

Implications for Diagnosis and Risk Stratification

The expanding knowledge of ILD genetics has direct implications for diagnostic algorithms and risk stratification. Identifying specific genetic mutations can help confirm a diagnosis, especially in cases with atypical clinical or radiological features. For instance, a patient with suspected IPF but without the classic HRCT pattern might have their diagnosis solidified by the presence of a known pathogenic telomerase mutation. This can prevent unnecessary invasive procedures and guide earlier intervention. The use of AI in detecting subtle ILD changes also points to the need for more precise diagnostic tools.
Genetic testing can also identify individuals at higher risk for developing ILD, particularly within families with a history of the disease. While not every carrier of a predisposing mutation will develop ILD, understanding this risk allows for closer monitoring and potentially earlier intervention if symptoms emerge. This proactive approach could shift the management paradigm from reactive treatment of established disease to preventative strategies or early disease modification. For clinicians seeking a comprehensive overview of respiratory conditions, the Oxford Handbook of Respiratory Medicine offers a valuable reference.
Genetic information can inform prognosis. Patients with certain genetic variants, such as those affecting telomere maintenance, often have a more aggressive disease course and a poorer response to standard antifibrotic therapies. This knowledge can help clinicians counsel patients and families more accurately about disease progression and treatment expectations. It also highlights the need for personalised medicine approaches, where treatment decisions are tailored to an individual's genetic profile.
But the utility of genetic testing is not universal. The penetrance of many ILD-associated genetic variants is incomplete, meaning not everyone with a mutation will develop the disease. This complicates genetic counselling and risk prediction. The presence of a genetic variant does not always dictate the clinical course, and environmental factors still play a

significant role in disease manifestation. Therefore, genetic information must be interpreted within the broader clinical context, including patient symptoms, imaging, and lung function tests.

Future Directions: Targeted Therapies and Prevention

The ultimate goal of understanding ILD genetics is to develop more effective, targeted therapies. Identifying specific genetic pathways that drive fibrosis opens avenues for novel drug development. For example, therapies aimed at restoring telomere function or modulating mucin production could be highly effective for patients with specific genetic mutations. This moves beyond the current broad-spectrum antifibrotic agents, which offer limited efficacy and significant side effects for many patients.

Research is actively exploring how genetic insights can be translated into clinical practice. This includes developing gene-editing technologies to correct pathogenic mutations or designing small molecules that interfere with the downstream effects of these mutations. While these approaches are still in early stages, they represent a significant shift towards precision medicine in ILD. The complexity of these diseases means that combination therapies, potentially targeting multiple genetic pathways, may be necessary for optimal outcomes.

The field is also grappling with the ethical considerations surrounding genetic testing for ILD. Issues such as incidental findings, the psychological impact of knowing one's genetic predisposition, and equitable access to testing and subsequent therapies must be carefully addressed. As genetic testing becomes more widespread and affordable, clear guidelines for its use in ILD are essential to ensure responsible implementation. The journey from genetic discovery to routine clinical application is long, but the trajectory is clear: genetics will increasingly define how we understand and treat interstitial lung diseases.

CLINICAL IMPLICATIONS

The growing understanding of ILD genetics is a double-edged sword for the busy clinician. On one hand, it offers the promise of more precise diagnoses and, eventually, targeted therapies. On the other, it adds another layer of complexity to an already challenging group of diseases. We are moving beyond simply classifying ILD by its radiological pattern; now, we must consider the molecular drivers, which means a more detailed patient history, including family history, becomes even more critical.

For now, the immediate impact is primarily diagnostic and prognostic. Identifying a specific genetic mutation can clarify an ambiguous case, potentially sparing a patient an invasive biopsy or guiding a more accurate discussion about disease progression. But the incomplete penetrance of many variants means a positive genetic test is not a crystal ball. Clinicians must temper genetic insights with the full clinical picture, avoiding over-reliance on a single data point.

The pharmaceutical industry is certainly watching these developments. As genetic subtypes become clearer, so do opportunities for highly targeted drug development. This could lead to a fragmentation of the ILD market, with therapies designed for specific genetic profiles rather than broad populations. This shift will demand more sophisticated diagnostic pathways and a greater emphasis on genetic counselling in specialist centres. The current antifibrotic agents are a start, but the future of ILD treatment will undoubtedly be more stratified.

EDITORIAL & AI STANDARDS

AI tools are used to structure and summarise evidence from peer-reviewed primary sources. Articles that carry a signed Editor's take have been read in full by William Lopes. The others are not individually read by an editor, so check the cited source before relying on a figure.

REFERENCES

1. 1. Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet. 2022;400(10354):769-786. doi:10.1016/S0140-6736(22)01052-2
2. 2. Brixey AG, Oh AS, Alsamarraie A, Chung JH. Pictorial Review of Fibrotic Interstitial Lung Disease on High-Resolution CT Scan and Updated Classification. Chest. 2024;165(4):908-923. doi:10.1016/j.chest.2023.11.037
3. 3. Casal A, Suárez-Antelo J, Riveiro V, et al. Smoking-related interstitial lung disease: A narrative review. Chron Respir Dis. 2024;21:14799731241291538. doi:10.1177/14799731241291538
4. 4. Luppi F, Sebastiani M, Silva M, et al. Interstitial lung disease in Sjögren's syndrome: a clinical review. Clin Exp Rheumatol. 2020;38 Suppl 126(4):291-300. PMID:33095142
5. 5. Kadura S, Raghu G. Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review. Eur Respir Rev. 2021;30(162). doi:10.1183/16000617.0123-2021
6. 6. Antoniou KM, Margaritopoulos GA, Tomassetti S, Bonella F, Costabel U, Poletti V. Interstitial lung disease. Eur Respir Rev. 2014;23(131):40-54. doi:10.1183/09059180.00009113

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com